Matthias Guckenberger, Professor and Chairman of Department of Radiation Oncology at USZ & UZH, shared a post on LinkedIn about an article he co-authored with colleagues:
“Metastases-directed stereotactic radiotherapy (SRT) is safe, also in the setting of concurrent treatment with modern biological anti-cancer therapy (BCT)
Prospective multicenter study of 27 institutions
514 SRTs (271 cranial & 243 extracranial) concurrent with BCT
- ≥grade 3 acute adverse events: 5.3%; 3 patients with grade 5 events
- ≥grade 3 late adverse events: 6.3%; 2 patients with grade 5 events
- SRT with uninterrupted BCT was not associated with increased severe acute or late adverse events
- Interruption of BCT during SRT was not associated with worse PFS and OS
Link to full text article.
Huge thanks to all contributing centers and colleagues !”
Title: Adverse Events After Metastases-Directed Stereotactic Radiotherapy and Biological Cancer Therapy
Authors: Esmée L Looman, Stephanie G C Kroeze, Jana Schaule, Mathieu Spaas, Klaus Henning Kahl, Joost J C Verhoeff, Famke L Schneiders, Oliver Blanck, Fabian Lohaus, Susanne Rogers, David Kaul, Sergi Benavente, Stephanie E Combs, Georgios Skazikis, Kynann P Aninditha, Ilinca Popp, Friederike L A Koppe, Hans Geinitz, Katrien de Jaeger, Shankar Siva, Susanne Stera, Andrea Wittig, Victor Lewitzki, Franziska Eckert, Markus M Schymalla, Matthias Guckenberger
More posts featuring Matthias Guckenberger.
